Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Erlangen-Nürnberg Medical School
M.D. Anderson Cancer Center
Jazz Pharmaceuticals
Dana-Farber Cancer Institute
AstraZeneca
Mayo Clinic
Baylor College of Medicine
Avacta Life Sciences Ltd
Brigham and Women's Hospital
University of Nebraska
NRG Oncology
Big Ten Cancer Research Consortium